ArticleBMC gastroenterology2025
Elucidating the role of AC026412.3 in hepatocellular carcinoma: a prognostic disulfidptosis-related LncRNAs model perspective.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disulfidptosis: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disulfidptosis—a newly characterised mode of regulated cell death implicated in tumorigenesis—exhibits undefined prognostic utility in hepatocellular carcinoma (HCC), particularly concerning disulfidptosis-related long non-coding RNAs (DRLs). Integrating transcriptomic and clinical data from The Cancer Genome Atlas, we identified 807 DRLs and constructed a prognostic signature via univariate Cox regression, LASSO-Cox penalisation, and multivariate Cox analysis. The resulting four-DRL signature (AL031985.3, TMCC1-AS1, AL590705.3, AC026412.3) stratified patients into distinct risk cohorts, with high-risk groups demonstrating significantly reduced overall survival (OS; log-rank P < 0.001) and hazard ratios independent of conventional clinicopathological variables. Model discrimination was robust across multiple metrics: time-dependent receiver operating characteristic curves yielded AUCs of 0.750 (95% CI: 0.676–0.817) at 1 year, 0.709 (0.637–0.781) at 3 years, and 0.720 (0.641–0.799) at 5 years, outperforming established staging systems. Concordance indices (C-index: 0.681) and principal component analysis further validated stratification efficacy. Functional annotation linked the signature to extracellular matrix dysregulation, epithelial-mesenchymal transition, and immunosuppressive microenvironments. High-risk patients exhibited elevated tumour mutational burden (P = 0.04), increased M0 macrophage infiltration, and heightened tumour immune dysfunction and exclusion (TIDE) scores (P < 0.001)—indicating impaired immunotherapy response. Pharmacogenomic profiling revealed enhanced sensitivity to five agents in high-risk subgroups (BDP-00009066, GDC0810, Osimertinib, Paclitaxel, YK-4-279; all P < 0.01). Critical experimental validation confirmed AC026412.3 as an oncogenic driver: significantly overexpressed in HCC tissues (P < 0.001) and cell lines, its knockdown suppressed proliferation, invasion, and migration in vitro. In vivo models demonstrated its necessity for angiogenesis (chorioallantoic membrane assay), primary tumour growth (orthotopic implantation), pulmonary metastasis, and epithelial-mesenchymal transition activation. This molecularly annotated signature enables precise prognostic stratification and guides personalised therapeutic strategies in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.